TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) announced today that it will present experimental results for its previously disclosed CGEN-54, an MCP-1 antagonist therapeutic candidate, at GTCBio’s 5th Cytokines and Inflammation Conference (January 29-30, 2007, Breckenridge, Colorado).
